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To determine the prevalence of Hepatitis E virus (HEV) in
industrialized nations, we analyzed the excretion of HEV strains
by the populations of Spain, France, Greece, Sweden, and the
United States. Twenty of 46 (43.5%) urban sewage samples col-
lected in Barcelona from 1994 to 2002 tested positive for HEV.
We identified 15 HEV strains, which were similar to two HEV
isolates previously described in Barcelona in clinical samples
and to strains from diverse geographic HEV-nonendemic areas.
We also identified two HEV strains in sewage samples from
Washington, D.C., and Nancy, France; these samples were also
positive for Hepatitis A virus. In addition, we studied the role of
pigs as a reservoir for HEV and identified one new swine HEV
strain. Our results suggest that HEV may be more prevalent
than previously considered in industrialized countries and that
variants of the virus circulate simultaneously in one region. 
H
epatitis E virus (HEV) infection is a major cause of epi-
demic and acute sporadic hepatitis in many areas of Asia,
Africa, and Mexico (1,2), where HEV is considered endemic.
HEV is an RNA virus enterically transmitted with a single
serotype, which affects mainly young adults. In countries
where the virus is endemic, HEV is associated with >50% of
sporadic acute hepatitis cases. The disease is self-limited but
sometimes has severe complications and a high case-fatality
rate, particularly in pregnant women (approximately 20%) (3).
North America and Europe have traditionally been considered
nonendemic for HEV; most HEVinfections in those regions are
considered to be imported, although seroprevalence ranges
from 1% to 5% (4). In the last few years, some HEV strains
associated with sporadic acute hepatitis have been isolated
from human serum samples in North America (5) and Europe
(i.e., Italy, Greece, Spain, and the United Kingdom) (6,7).
Molecular analyses have shown that these strains form a group
of HEV isolates that are genetically divergent compared with
strains from HEV-endemic countries (8). 
Evidence also exists that some animals can be reservoirs of
HEV; for example, HEV infection has been demonstrated in
swine (9). Swine and human HEVstrains from a particular geo-
graphic region often appear to be closely related genetically
(6,9–11). Transmission of HEV infection during outbreaks pri-
marily occurs through contaminated water (12). Unlike other
enterically transmitted infections, person-to-person transmis-
sion of HEV occurs infrequently (13).
We investigated the level of infection in regions where HEV
is considered nonendemic by analyzing the excreted virus in
the urban sewage of diverse geographic areas. The excretion
and epidemiology of HEV was compared to the excretion and
epidemiology of Hepatitis A virus (HAV) (14). We also ana-
lyzed swine fecal samples to identify evidence of HEV infec-
tion in pigs. 
Material and Methods
Sewage Samples
Urban sewage samples were collected at the entry of a water
treatment plant receiving 670,000 m3/day of waste products
from Barcelona, Spain (population: approximately 1.8 million
inhabitants). From the sewage network of this city, we collect-
ed 26 samples (taken every 2 weeks) from June 2000 to May
2001 and 8 samples (taken monthly) from June 2001 to January
2002. We also tested 12 sewage samples previously collected
from the same area and stored at –80°C: 2 from 1994, 2 from
1995, 2 from 1996, 3 from 1997, 1 from 1998, and 2 from
1999. Each sample was collected in a sterile 500-mL polyeth-
ylene container, kept at 4°C for <8 h until viral particles were
concentrated in phosphate-buffered saline (PBS, pH 7.3), and
stored at –80°C. 
We obtained urban sewage samples from other countries, as
follows: five samples from Patras, Greece, in June–July 1999;
five samples from Washington, D.C., United States, in
December 1999; four samples from Nancy, France, in March
1998; and four samples from Umeå, Sweden, in
September–October 1997. These samples were collected and
shipped, frozen, to Spain where the viral particles were concen-
trated in PBS and stored at –80°C. 
Human Serum Samples
We contacted 13 patients seen in the emergency room of the
Hospital General Valle Hebron, Barcelona, Spain, for acute
hepatitis over the last 12 years who had tested positive for
immunoglobulin (Ig) G anti-HEV. A follow-up serum sample
was collected in order to evaluate the durability of antibody
response. These samples were stored at –80°C.
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Seventy-three serum samples were obtained from healthy
pigs in three commercial herds in Catalonia, Spain: 43 weaned
pigs (3–9 weeks old), 10 fattening pigs (10–22 weeks old), 8
gilts (young sows), and 12 sows. Blood samples were taken
aseptically from the vena cava or jugular vein, and the serum
obtained by centrifugation was stored at –80°C until tested.
Thirty fecal samples from pigs of various ages were collect-
ed from the same three herds. Individual samples were taken
and later pooled with samples from 3–5 animals in the same
age group. Samples from the “fattening” pigs were collected
from different places in their pens, each one containing 10–15
animals. 
Serologic Tests of Human Serum Samples
Commercially available enzyme immunoassays (Abbott
Laboratories, Abbott Park, IL) were used for the detection of
hepatitis B surface antigen, IgM anti–hepatitis B core, IgM
anti-hepatitis C virus (HCV), anti-HAV, and IgG anti-HEV.
HCV-RNA was analyzed by polymerase chain reaction (PCR)
(Amplicor HCV, monitor test version 2.0; Hoffman-La Roche
Inc., Nutley, NJ).
Serologic Tests of Swine Serum Samples
A commercially available enzyme immunoassay (Abbott
Laboratories) was used, with some modifications to detect IgG
anti-HEV in pigs. Hyperimmune serum from a pig experimen-
tally inoculated with the porcine-HEV strain and preimmune
serum from a noninoculated pig and a Rhesus Monkey (Macaca
mulatta) (serum donated by S.U. Emerson and R.H. Purcell)
were used as positive and negative controls, respectively. 
Control Viruses
Fecal suspensions obtained from Rhesus Monkeys infected
with HEV Barcelona (BCN) strain (10% in PBS, pH 7.3) were
used as positive control for the PCR analysis. The strain that
infected the monkeys was isolated from sewage in Barcelona
and is genetically similar to Indian strains (15). Viral suspen-
sions were stored at –80°C.
Concentration of Viral Particles from Sewage Samples
Recovery of viral particles was carried out as described pre-
viously (16,17). Briefly, a 40-mL sewage sample was ultracen-
trifuged (110,000 × g for 1 h at 4°C) to pellet all viral particles
together with any suspended material. The sediment was elut-
ed by using 4 mL 0.25 N glycine buffer, pH 9.5, and the sus-
pended solids were separated by centrifugation at 12,000 × g
for 15 min. Viruses were finally pelleted by using ultracentrifu-
gation (110,000 × g for 1 h at 4°C), resuspended in 0.1 mL
PBS, and stored at –80°C.
Concentration of Viral Particles from Swine Feces Samples
A protocol similar to the one used for sewage samples was
carried out to concentrate viral particles from swine feces sam-
ples; 1 g of a pool of feces was eluted in 4 mL 0.25 N glycine
buffer, pH 9.5, and centrifuged (10,000 × g for 15 min) to sep-
arate suspended solids. The supernatant was finally ultracen-
trifuged (110,000 × g for 1 h at 4°C), and viruses were resus-
pended in 0.1 mL PBS and stored at –80°C.
Nucleic Acid Extraction
Viral nucleic acids from viral particles were extracted as
described previously (18) after we selected the procedure that
is more likely to eliminate potential inhibitors of reverse tran-
scription (RT)–PCR. The method is based on the use of guani-
dinium isothiocyanate and adsorption of the nucleic acids to
silica particles. Briefly, 50 µLof viral concentrate was added to
a mixture of 50 µL of silica particle suspension and 900 µL of
lysis buffer. The mixture was incubated at room temperature
for 10 min and washed twice in 1 mL of washing buffer (12 g
of guanidine thiocyanate in 10 mL of Tris-EDTA), twice more
in 70% ethanol, and once in acetone. The pellet obtained after
the complete evaporation of acetone was resuspended with 50
µL of elution buffer (49.4 µL of dithiothreitol [DTT] and 0.6
µL of RNase inhibitor [Applied Biosystems, Foster City, CA]).
The extracted nucleic acids were then used for cDNAsynthesis
and amplification of the HEV and HAV genomes.
Enzymatic Amplification
To detect viral RNA, we used a seminested RT-PCR with
degenerated primers as described (19). Five µL of the extract-
ed nucleic acids and a 10-fold dilution (corresponding to 5 µL
and 0.5 µL of serum, 50 mg and 5 mg of feces, and 2 mL and
0.2 mL of sewage) were analyzed by RT-PCR, plus 1.5 mM of
MgCl2, PCR Gold Buffer (10 mM Tris-HCl, pH 8.3, 50 mM
KCl) (Applied Biosystems), 0.01 M DTT, 10 nmol of each
dNTP, and 25 pmol of the reverse primer (HEVORF2con-a1; nt
6454–6479 in HEV United States [US1] strain) in a total vol-
ume of 10 µL. The mixture was incubated at 95°C for 5 min
before the addition of 10 U of ribonuclease inhibitor (Applied
Biosystems) and 50 U of RT mouse mammary leukemia virus
(Applied Biosystems). After 30 min at 42°C, the mixture was
heated again at 95°C for 5 min. 
For a typical one-step reaction, we used 10 µL of the cDNA
solution. Amplification was carried out in a 50-µL reaction
mixture containing PCR Gold Buffer (Applied Biosystems),
1.2 mM MgCl2, 2 U of Ampli Taq Gold (Applied Biosystems)
25 pmol of the forward primer (HEVORF2con-s1; nt
6283–6306 in the HEV US1 strain). The first cycle of denatu-
ration was carried out for 5 min at 95°C, followed by 35 cycles
at 94°C for 60 s, annealing at 55°C for 30 s, and extension at
72°C for 1 min. All amplifications were completed with a 10-
min, 72°C extension period. For a second PCR amplification
cycle, we added 1 µL of the first-round product to a new batch
of 50-µL reaction mixture containing 25 pmol of each primer
(HEVORF2con-a1 and HEVORF2con-s2; nt 6332–6353 in
US1 strain). This second PCR was performed under the same
conditions. The products were analyzed by agarose gel elec-
trophoresis with ethidium bromide stain. A region of 148
nucleotides within open reading frame (ORF) 2 of the HEV
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region of 287 nucleotides within ORF1 were carried out.
Primers used were HEVORF1con-s1 (nt 2–25),
HEVORF1con-s2 (nt 50–70), HEVORF1con-a1 (nt 397–419),
and HEVORF1con-a2 (nt 313–336). The primer positions are
relative to HEV US1 strain. Nested RT-PCR was carried out for
detecting HAV genome in sewage samples as described (14),
amplifying fragments within the 5´ nontranslated region (NTR)
region and the VP1/A2 junction region.
Quality Control of the Amplification Method
Standard precautions were used for all procedures to reduce
the possibility of sample contamination by amplified DNA
molecules. A negative control was added every two samples.
Virus-positive amplification results were confirmed by
sequencing.
Sequencing and Analysis of the Viral Genome
The amplicons obtained after the nested PCR were purified
by using the QIAquick PCR purification Kit (QIAGEN GmbH,
Inc., Hilden, Germany), following the manufacturer’s instruc-
tions. Both strands of the purified DNA amplicons were
sequenced with the ABI PRISM BigDye Terminator Cycle
Sequencing Ready Reaction kit with Ampli Taq DNA poly-
merase FS (Applied Biosystems), following the manufacturer’s
instructions. We checked results using the ABI PRISM 3700
DNA analyzer (Applied Biosystems). We compared the
sequences with those present in GenBank and the European
Molecular Biology Library by using the basic BLAST program
of the National Center for Biotechnology Information (avail-
able from: URL: http://www.ncbi.nlm.nih.gov/BLAST/).
GenBank accession numbers of the HEV strains sequences
characterized previously and used for phylogenetic studies are
listed in Table 1.
Alignments of the sequences were carried out by using the
ClustalX 1.8 program (available from: ftp://ftp-igbmc.u-stras-
bg.fr/pub/ClustalX/). Phylograms were generated by the
UPGMA algorithm using the NEIGHBOR program. The
robustness of the grouping was determined by bootstrap resam-
pling of the multiple sequence alignments (1,000 sets) with the
programs SEQBOOT, DNADIST, NEIGHBOR, and CON-
SENSE. The output graphics of the trees were created with the
TREEVIEW package, version 1.5 (20). 
Results
Sewage Samples
Forty-six sewage samples from Barcelona were collected
from 1994 to 2002. Of the samples collected before 2001, a
total of 4 (14.8%) of 27 tested positive for HEV RNA; this pro-
portion increased to 84.2% (16/19) among the samples collect-
ed from 2001 to 2002 (Table 2). After performing sequence
analysis of the amplified region within ORF2, we identified 15
new HEV isolates (BCN2–BCN16) (GenBank accession nos.
in Table 1).
HAV RNA was detected in 21 (77.8%) of 27 sewage sam-
ples that were collected in Barcelona from 1994 to 2000 and
tested for the presence of HAV. Previous studies in the same
area showed 31 (57.4%) of 54 sewage samples positive for
HAV from 1994 to 2000 (14).
We also tested for the presence of HEV RNA in sewage
samples from other countries where HEV was previously con-
sidered nonendemic. One of five samples from Washington,
D.C., and one of four samples tested from Nancy, France,
were positive, showing two new HEV strains (W1 and N1).
HEV RNA was not detected in any of the four samples from
Umeå, Sweden, or the five samples from Patras, Greece. HAV
RNA was detected in all four countries: All U.S. sewage sam-
ples, three of four samples from France, one of five samples
from Greece, and one of four from Sweden tested positive for
HAV.
Human Serum Samples
Follow-up serum samples from 13 seropositive acute hepa-
titis patients from Barcelona were analyzed to evaluate the
durability of antibody response. None of these samples showed
the RNA of the virus. IgG anti-HEV was undetectable in 7
(53.8%) of 13 of these follow-up samples. Seven of eight
seropositive patients were found to be seronegative 2 to 12
years after the initial test. 
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Table 1. Nucleotide sequence accession numbers for Hepatitis E virus 
strains 
Origin  Abbreviation  GenBank accession no.
Described in previous studies 
Barcelona  BCN  AF058684 
G1  AF110391  Greece 
G2  AF110392 
Italy  It  AF110390 
Austria  Au  AF279123 
US1  AF060668 
US2  AF060669 
United States 
Sw
a  AF082843 
Mexico  M  M74506 
Pakistan  P  M80581 
Burma  B  M73218 
C1  D11092 
C2  AJ272108 
China 
C3  AF082094 
India  I  X98292 
Reported in this study 
BCN2  AF491004 
BCN3  AF490985 
BCN4  AF491003 
Barcelona 
BCN5–BCN16  AF490986–AF490997
Washington, D.C., United States  W1  AF490998 
Nancy, France  N1  AF490999 
VH1  AF491000  Barcelona, Spain
b 
VH2  AF491001 
Catalonia, Spain
a  Por1  AF491002 
aOriginated from swine. 
bStrains reported previously (15), but their sequences within open reading 
frame 2 used for phylogenetic analysis in this study are new. Animal Samples
Swine serum and fecal samples from pigs in three different
herds in Catalonia, Spain, were tested. A total of 10 (13.7%) of
73 serum samples were positive for anti-HEV IgG antibodies
(all were obtained from fattening pigs or the oldest pigs from
the same herd). A total of 55 serum samples from pigs of dif-
ferent ages were taken at this farm. The distribution of seropos-
itive animals was as follows: 4 (40.0%) of 10 samples from fat-
tening pigs, 2 (40.0%) of 5 from gilts, 1 (33.3%) of 3 from
primiparous sows, and 3 (42.8%) of 7 from multiparous sows.
Pigs from the other two farms were seronegative for HEV.
None of the serum samples were positive for HEV by RT-PCR. 
The HEV genome was amplified by RT-PCR in 6 of 12 fecal
samples collected in the herd with seropositive animals. We
detected HEV in one of the two pools from pigs 3 weeks old, in
one of two pools from pigs 5 weeks old, in two of two pools
from pigs 8 weeks old, in one of two pools from fattening pigs,
and in the pool of feces from primiparous sows. After sequence
analysis, we identified one new swine HEV strain (Por1).
Sequence Analysis of the HEV RNA Genomes
Phylogenetic analysis showed that all the sequences detect-
ed were grouped with strains isolated in countries where HEV
was considered nonendemic (Figure 1). The nucleotide
sequence alignment of the detected strains with other HEV
strains is shown in Figure 2. BCN2–9, BCN11–BCN14, and
BCN16 shared a 91.0% to 99.2% similarity. They were closely
related to VH1 (94.3% to 98.4% identity) and VH2 (91.0% to
95.1%), two strains isolated from clinical samples in the same
area (Barcelona), previously described (15), and G1 (92.7% to
96.7%), an isolate from Greece. Two isolates (BCN10 and
BCN15) showed substantially different sequences, sharing
86.5% to 89.2% and 87.2% to 91.9% similarity with the rest of
strains detected in Barcelona. Aprevious study (15) in the same
area with specific primers for HEVstrains from areas where the
virus is endemic identified one isolate (BCN), which was close-
ly related to Indian strains. Nucleotide sequence identities
among this isolate and the new ones from Barcelona ranged
from 79.7% to 83.7%.
The HEVstrain identified in sewage from Washington (W1)
was closely related to other isolates from the United States,
sharing 91.0% to 91.9% identity with US1 and US2 strains
obtained from human serum samples, and 98.4% with a swine
strain (Sw) also isolated in the United States. BCN15, from
Barcelona, was also similar to those isolates from the United
States, showing 89.4% to 91.9% nucleotide sequence identity.
The sample from Nancy (N1) was highly similar (92.7%) to
VH1. All HAV strains were genotype IA, except the Swedish
isolate (IB).
The nucleotide sequences of the isolates from swine were
identical and, when compared with other isolates, the Por1
strain exhibited a similarity of 92.7% with G2 and 87.0% to
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Table 2. Summary of results of HEV and HAV found in urban sewage samples  
Site  Period of sampling  Positive HEV samples/total analyzed  Positive HAV samples/total analyzed 
Barcelona, Spain  October–November 1994  0/2  1/2 
  May–June 1995  0/2  1/2 
  February–April 1996  1/2  1/2 
  September–October 1997  0/3  2/3 
  January 1998  0/1  1/1 
  March–April 1999  1/2  2/2 
  June–December 2000  2/15  13/15 
  January 2001–January 2002  16/19  NT 
Total (for Barcelona)    20/46 (43.5%)
b  21/27 (77.8%)
b 
Nancy, France  March 1998  1/4  3/4 
Umeå, Sweden  September–October 1997  0/4  1/4 
Patras, Greece  June–July 1999  0/5  1/4 
Washington, D.C., United States  December 1999  1/5  5/5 
aHEV, Hepatitis E virus; HAV, Hepatitis A virus; NT, not tested. 
b% of positive samples. 
Figure 1. Unrooted phylogenetic tree showing the relationship over a
123-bp fragment within open reading frame 2 between representative
Hepatitis E virus strains reported in this study and other isolates from
genotype I (C1, China; P, Pakistan; I, India; BCN, Barcelona, Spain; and
B, Burma), genotype II (M, Mexico), genotype III (US1 and US2, United
States; Sw, swine, United States; G1 and G2, Greece; It, Italy; and Au,
Austria), and genotype IV (C2 and C3, China). Strains from Barcelona,
Spain, Washington, D.C., United States, and Nancy, France, are in bold.91.0% with isolates from sewage in Barcelona. The results of
translating nucleotide sequences into amino acid sequences
showed that the substitutions in strains detected in Barcelona
(including the one from pigs) were mainly located in the third
codon position and were conservative (Figure 3). Two strains
(BCN9 and BCN14) showed two nonconservative substitutions
in the same position.
Discussion
In previous studies, investigating the viruses present in a
population’s sewage has produced reliable information about
the strains infecting that population; this type of analysis
detects the viruses that cause clinical and subclinical infections
in the population (14).  In our study, we showed the presence of
HEV strains during a period of several years in raw urban
sewage from an area previously considered nonendemic for the
virus. We also demonstrated the presence of HEV in other
industrialized countries by testing urban sewage samples from
diverse geographic areas. We identified 17 new HEV strains
from sewage samples in Barcelona, Spain (15 isolates);
Washington, D.C., United States (1 isolate); and Nancy, France
(1 isolate); these locations also produced a high percentage of
HAV-positive sewage samples. 
The amplified region of the viral genomes detected in this
study was sequenced; the diversity we observed indicates the
absence of a unique HEV outbreak in the population and shows
that a diverse number of strains are simultaneously circulating.
Only the viral genomes from the samples showing the higher
viral concentration (Por1 and W1) could be sequenced in ORF1
by using the described primers. Y. Wang et al. (21) noted that
negative results were observed in serum samples positive in the
ORF2 when using these ORF1 primers, suggesting a lower
level of efficiency in the amplification reactions compared with
the ORF2 primers applied in the study. The phylogenetic analy-
sis of short sequences has previously produced trees similar in
structure to those observed with longer sequences (21,22). The
strains we describe may be most closely related to genotype III,
one of the four genotypes described by G.G. Schlauder and I.K.
Mushahwar (8). Larger fragments should be sequenced in order
to confirm these results.
The prevalence of HAV infection in Catalonia, where most
of the sewage samples were collected, is 67.8% (23); in this
area, HAV is considered to be of intermediate endemicity. In
the same area of Barcelona, 57.4% of the sewage samples col-
lected from 1994 to 2000 showed HAV; these HAV strains were
found to be closely related to the HAV strains identified in the
clinical samples for the same period (14).
HEV can be detected in the stool of most patients infected
with HEV, with duration of fecal shedding generally limited to
9–12 days (24). If we compare the transmission of HEV and
HAV in this region, since the time after infection that HEV is
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Figure 2. Nucleotide alignment of the amplified fragment within ORF2 from some representative isolates in this study with other Hepatitis E virus
strains. Dots indicate sequence identities.
Figure 3. Amino acid alignment from representative isolates in this
study with other Hepatitis E virus strains. Amino acid sequences from
BCN3–BCN8, BCN10–BCN13, and BCN16 are identical to BCN2. Dots
indicate sequence identities.excreted does not appear to be longer than the time after infec-
tion that HAV is excreted, we find that HEV infections may be
more frequent than previously considered. That 84.2% of
sewage samples collected during 2001 and 2002 were HEV
positive suggests that the prevalence of HEV infections may be
underestimated. 
In our study we also analyzed samples from three commer-
cial pig farms; only one of these farms had pigs positive for
HEV. However, from that one farm, antibodies and virus were
detected in animals of different ages, suggesting that HEV is
widespread among animals in infected herds. Our serologic
results showed that although only 13.7% of samples were pos-
itive, all of them were from animals >10 weeks (fattening pigs
and sows). Since that farm worked with a farrow-to-finish sys-
tem, these results may indicate a slow diffusion of infection
within the farm. The fact that adult sows had positive serolog-
ic and virologic test results suggests their possible role as reser-
voirs on the farm. The swine HEV strain identified in these ani-
mals has been found to be related to the human strains detect-
ed (87.0% to 91.0%). Previous studies also reported that swine
HEV isolates identified in the United States (9), Taiwan (11),
and Japan (10) were closely related to human HEV isolates
obtained from the same geographic areas. In fact, swine HEV
isolates seem to be more similar to human HEV isolates from
the same area than they are to swine HEV isolates from differ-
ent geographic areas (25). Swine HEV isolates identified in
Canada and the Netherlands have been clustered with previous-
ly described European and American human or swine isolates
(26,27). Finally, veterinarians and persons working with pigs
have been shown to at a greater risk for HEV infection. Meng
et al. (28) reported that swine veterinarians were one and a half
times more likely to seroconvert to HEV infection, although
clearly multiple sources of exposure can exist. 
Most existing assays for antibody to HEV are enzyme
immunoassays that use recombinant-expressed proteins or syn-
thetic peptides representing antigenic domains from ORF 2 and
ORF 3, commonly from strains of at least two geographically
distinct HEV strains. The HEV strains used in these tests are
representative of those from countries with endemic HEV and
show some differences from recently identified strains in the
sequence of amino acids of several major epitopes as the region
near the carboxyl ends of ORF 2 and ORF 3. Some differences
are shown in amino acid sequences of strains from areas with
nonendemic and endemic virus in the amplified region, which
is located within a strongly reactive epitope (29). This diversi-
ty could be producing a lower level of sensitivity in the sero-
logic assays for these infections. A recent study from the
Hepatitis E Virus Antibody Serum Panel Evaluation Group
concluded that discrepant results among blood donor serum
samples show that anti-HEV seroprevalence data in countries
with nonendemic HEV may be unreliable and should be inter-
preted with caution (30). Our results also support this conclu-
sion.  As some authors have suggested (31), we show that IgG
antibodies a few years after the initial test are reduced to unde-
tectable levels in 53.8% of cases. In some cases, antibody lev-
els are reduced very early, after only 3–4 months, which makes
the diagnosis of HEV infection extremely difficult. Several
authors have suggested that some persons may not produce a
detectable antibody response at all (24). Balayan (3) also con-
sidered the prevalence of anti-HEV in areas endemic for HEV
to be much lower than expected, with a rate of 2.8% to 20.2%
in areas having a high proportion of HAV-seropositive persons.
In highly industrialized countries, anti-HEV has been regularly
found at a rate not exceeding 5%; in Spain, anti-HEV was
found in 1% to 3% of blood donors (32).
Specific information on the pathogenicity of the HEV
strains detected in Europe and the United States is not avail-
able; these data are required for evaluating the potential risk
associated with the infection. Using adequate specific tests
must be considered for the routine diagnosis of HEV infections
in patients with acute viral hepatitis not related to HAV in
industrialized countries, especially in asymptomatic patients
with unexplained elevated aminotransferase levels and in preg-
nant women. Our data suggest that HEV strains are more wide-
spread in the human population than previously thought and
endemic HEV infections are likely present in Europe and the
United States. More studies are warranted to characterize the
HEV infections detected and evaluate the sanitary risk that the
excreted HEV represents for humans.
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